CTSH · Q2 2025 Earnings
BullishCognizant
Reported July 30, 2025
30-second summary
Cognizant delivered 8.1% YoY revenue growth to $5.25B, raised the low end of FY revenue and EPS guidance, and posted a 1.4x book-to-bill with two >$1B mega deals in the quarter. The narrative shift is the more important signal: management is reframing agentic AI from a productivity tool inside existing contracts to a "new spend cycle" with proprietary IP layer ("IP on the Edge") as the moat. Near-term Q3 guidance implies deceleration to 4.6–6.1% YoY, but the booking trajectory and 40bps of H1 margin expansion against a 20–40bps full-year guide suggest operating leverage is intact.
Headline numbers
EPS
Q2 FY2025
$1.31
Revenue
Q2 FY2025
$5.25B
+8.1% YoY
Gross margin
Q2 FY2025
33.7%
Free cash flow
Q2 FY2025
$0.33B
Operating margin
Q2 FY2025
15.6%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $5.25B | +8.1% |
| EPS | $1.31 | — |
| Gross margin | 33.7% | — |
| Operating margin | 15.6% | — |
| Free cash flow | $0.33B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment performance
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Health Sciences | $1.551B | +6.2% |
| Financial Services | $1.547B | +6.9% |
| Products and Resources | $1.306B | +16.0% |
| Communications, Media and Technology | $0.841B | +3.1% |
Platform metrics
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| TTM Bookings | $27.8 billion |
| Bookings Growth YoY | 6% (TTM); 18% (Q2) |
| Book-to-Bill Ratio | 1.4x |
| Large Deals (≥$100M TCV) | 6 deals in Q2 (2 mega deals >$1B each) |
| Total Headcount | 343,800 |
| Voluntary Attrition (Tech Services, TTM) | 15.2% |
Profitability
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Adjusted Operating Margin | 15.6% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| North America | $3.912B | +8.1% |
| Europe | $1.002B | +9.6% |
| Rest of World | $0.331B | +4.7% |
| Capital Return to Shareholders YTD | $885 million (2025 planned: $2.0 billion) | — |
Management tone
Management's framing on AI shifted decisively from defense to offense. The five tone shifts in the analysis all point in the same direction: AI is no longer being pitched as productivity savings inside the existing book of business, but as a separate spend cycle that expands TAM.
The most consequential reframe is the move from "AI as productivity tailwind" to "agentic AI unlocking new revenue pools and spend cycles." Management's verbatim language — "we are building a new opportunity, one defined by identification at scale with new client spend cycles…a once-in-a-lifetime opportunity" — is unusually expansive for a company that has historically positioned itself as a steady share-taker. The signal is that Cognizant believes innovation-led deal economics (monetized linearly without being shared back with clients) are fundamentally different from productivity-led economics, and that mix shift is now underway.
The "IP on the Edge" positioning is the second meaningful shift. Cognizant is explicitly trying to escape the commoditizing IT services frame by claiming a proprietary layer — small language models, context engineering, Agent Foundry, TriZetto AI Gateway, CodeAssist. Whether this IP narrative holds up against frontier-model vendors moving downstream is the open question, but the assertion itself is new and management is willing to be measured against it.
The pilot-to-production transition is also being claimed quantitatively, not rhetorically: agentic projects scaled from 1,400 last quarter to 2,500 this quarter, and 56% of the 97% AI-adopting client base is now scaling GenAI with 78% of those showing measurable impact. The metric framework itself — moving from engagement counts to scaling maturity — is the tell that management thinks the conversation has changed.
The hedging is concentrated narrowly on the demand environment: Medicaid policy weighing on healthcare payers, tariff uncertainty in life sciences and products, and a low-end guide that "continues to assume further deterioration." The juxtaposition — bullish on AI structural opportunity, cautious on near-term discretionary — is internally consistent and the reason the FY guide narrowed rather than widened.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
James Fawcett · Morgan Stanley
How is the company pricing and incorporating its AI agents (100+ available) and IP into deals? How should investors think about the impact on business from pricing and opportunity standpoint?
Management explained that this is the first opportunity to make outcome-based pricing mainstream. They've invested in converting IP into platforms and reusable agent components in their foundry, creating differentiation and premium pricing potential. Innovation capital can be monetized linearly (unlike productivity which is shared with clients). The company sees opportunity to not just agentify processes but run them on behalf of clients, expanding total addressable spend. They're building ontology, small language models, and revolutionizing application development cycles.
Jamie Friedman · SIG
Can you update which of the three vectors (hyperproductivity, industrializing AI, agentifying enterprise) is ahead? Are any ahead of the others? And clarify whether innovation means short-duration discretionary spend.
Vector 1 (productivity) is significantly ahead and stable, with room for expansion from 30% to 50% machine-written code. Vector 2 and 3 (AI industrialization and agentification) are interlinked, with Vector 3 catching unexpected momentum. The company distinguishes innovation spend as cost reduction through innovation means (faster cycles, better experience, throughput), not necessarily discretionary. Examples include reducing KYC cycles from 4-5 days to 1-2 days using agents.
Jonathan Lee · Guggenheim Partners
Given embedded deceleration in back-half guidance, what 4Q exit rate is being assumed and which verticals/geographies are expected to decelerate vs. accelerate?
4Q exit rate guidance is wide: negative at low end, ~1% at midpoint, just under 4% at high end. Financial services expected to continue Y/Y growth for fourth consecutive quarter with innovation dollars unlocking (not just productivity). Healthcare seen as opportunity for productivity-led transformation (not innovation-led like financial services). Comms/tech now in positive territory. All three geographies performing well; U.S. performing significantly better than peers on a large base.
Amit Daryanani · Evercore ISI
How should we think about headcount growth in back half of year? Can 85% utilization rates sustain or will they dip? Are the 18% bookings gains coming at lower margins initially?
Headcount increased 7,500 (first YoY increase in 8 quarters) due to recent college graduate hiring. Back half will see smaller increases as company doubles down on AI-led productivity. Organic headcount growth approximately 3% (excluding Belcan acquisition). Large deals are priced correctly with templates in place; win rates have increased significantly. These deals are mainstream now and margin-accretive. Company achieved 40bps margin expansion in H1 2025 vs. guided 20-40bps for the period.
Brian Bergen · TD Cohen
How much is healthcare exposure to Medicaid/Medicare (BBB) headwind weighting on growth? Where are offsets in the business? How do you see healthcare moving through H2?
Management stated exposure to Medicaid/Medicare is limited. Primary exposure is commercial healthcare, payer business, provider business, and significant life sciences exposure. Life sciences is spending more and moving productivity dollars to innovation as technology drives new cycles. Healthcare opportunity is productivity-led (reducing operational overhead, which is the need of the hour). Company won a $1B healthcare deal driven by AI-led transformation. Sees healthcare as productivity opportunity rather than innovation-led spend.
What to watch into next quarter
Q4 exit-rate landing within the disclosed -0% to ~4% range. Management put midpoint at ~1%; anything materially below midpoint reopens the deceleration narrative the FY guide is implicitly denying.
Vector 3 (agentification) project count trajectory. Q1→Q2 went from 1,400 to 2,500. Sustaining a similar QoQ step (toward ~3,500–4,000) would validate the "new spend cycle" framing; flatlining would suggest pilots are not converting to production.
Large-deal cadence vs the 29-in-2024 / 17-in-2023 baseline. 3 mega deals YTD with 6 ≥$100M deals in Q2. Watch whether full-year mega-deal count exceeds the 2024 pace, which would validate the IP-led pricing thesis.
Adjusted operating margin holding ≥15.6% in Q3 given the 7,500-headcount step-up needs to absorb without margin compression. H1 already delivered 40bps expansion against a 20–40bps full-year guide — leaves narrow room in H2.
Healthcare segment growth sustaining above ~6% as Medicaid policy effects flow through payer discretionary budgets in H2. Health Sciences at +6.2% YoY this quarter is the canary.
Whether constant-currency revenue growth lands in the upper half of the narrowed 4.0–6.0% FY range — the narrowing itself was a partial cut at the high end of the prior range, and a low-end print would suggest the AI bookings momentum is not translating to in-period revenue as quickly as the bookings curve implies.
Sources
- Cognizant Q2 2025 press release (Exhibit 99.1, Form 8-K filed 2025-07-30) — https://www.sec.gov/Archives/edgar/data/1058290/000105829025000266/exhibit9916302025.htm
- Cognizant Q2 2025 earnings call commentary (per extraction; no full transcript available)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.